<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="at: [[inbox]]
Sanford Guide: HBV Treatment Indications for TreatmentWhen to TreatTreatment RegimensPreventionComments
Indications for Treatment  Treatment of Hepatitis B (HBV) infection."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle=Sanford Guide: HBV Treatment"><title>Sanford Guide: HBV Treatment</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.02120ee5abce9b994b1487466af3b5e4.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.9f18a39adf67bd3802b91e1815e3fa91.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init({securityLevel:"loose",theme:"base"})})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Sanford Guide: HBV Treatment</h1><p class=meta>最後更新於
Feb 8, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/HBV%20Treatment.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><p>at: <a class="internal-link broken">inbox</a></p><a href=#sanford-guide-hbv-treatment><h1 id=sanford-guide-hbv-treatment><span class=hanchor arialabel=Anchor># </span>Sanford Guide: HBV Treatment</h1></a><p>Indications for TreatmentWhen to TreatTreatment RegimensPreventionComments</p><a href=#indications-for-treatment><h3 id=indications-for-treatment><span class=hanchor arialabel=Anchor># </span>Indications for Treatment</h3></a><ul><li>Treatment of Hepatitis B (HBV) infection.</li><li>The following are key indicators: HBeAg status, HBV viral load (HBV DNA), elevated liver enzymes (ALT level), cirrhosis. For HBeAg+ patients treatment is typically deferred for 3-6 months to observe spontaneous seroconversion from HBeAg+ to negative.</li><li>Hepatitis B genome may be present but hard to detect. Only evidence may be presence of HBcAb with negative HBsAg and negative HBsAb. Such patients at risk of reactivation if immunosuppressed for cancer chemotherapy or transplantation. See HBV reactivation for details</li></ul><a href=#when-to-treat><h3 id=when-to-treat><span class=hanchor arialabel=Anchor># </span>When to Treat</h3></a><ul><li>The following are key indicators: HBeAg status, HBV viral load (HBV DNA), elevated liver enzymes (ALT level), cirrhosis. For HBeAg+ patients treatment is typically deferred for 3-6 months to observe spontaneous seroconversion from HBeAg+ to negative.</li></ul><p>| HBeAg Status | HBV DNA</p><table><thead><tr><th>(Viral Load)</th><th>ALT</th><th>Fibrosis*</th><th>Treatment**</th><th>Comments</th><th></th></tr></thead><tbody><tr><td>Pos</td><td>>20,000</td><td>&lt;2x ULN</td><td>F0-F2</td><td>Observe</td><td>Low efficacy with current Rx; biopsy helpful in determining whether to Rx.  Lean toward Rx if older age or + Family Hx HCC</td></tr><tr><td>Pos</td><td>>20,000</td><td>&lt;2x ULN</td><td>F3-F4</td><td>Treat: IFN or NUC</td><td><strong>No IFN if decompensated cirrhosis</strong></td></tr><tr><td>Pos</td><td>>20,000</td><td>>2x ULN</td><td>Any</td><td>Treat: IFN or NUC</td><td>IFN has higher chance of seroconversion to HBeAg Negative and HBsAg Negative status.</td></tr><tr><td>Neg</td><td>&lt;2000</td><td>&lt;1x ULN</td><td>Any</td><td>Observe</td><td>Might Treat if F4; <strong>No IFN if decompensated cirrhosis.</strong></td></tr><tr><td>Neg</td><td>2,000-20,000</td><td>&lt;2x ULN</td><td>F0-F2</td><td>Observe</td><td> </td></tr><tr><td>Neg</td><td>2,000-20,000</td><td>&lt;2x ULN</td><td>F3-F4</td><td>Treat: NUC (of IFN)</td><td>NUCs favored if HBeAg negative; Treatment duration ill-defined.  Certainly > 1 year, likely chronic Rx (indefinitely)</td></tr><tr><td>Neg</td><td>>20,000</td><td>>2x ULN</td><td>Any</td><td>Treat: NUC or IFN</td><td>NUCs favored if HBeAg negative; Treatment duration chronic /  indefinite</td></tr><tr><td>References: AASLD HBV Treatment Guidelines (
<a href=https://www.aasld.org rel=noopener>www.aasld.org</a>); <em>Hepatology</em> 50:1, 2009.</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table><ul><li>Liver Biopsy or fibrosure assay is helpful in determining when and how to treat.
** Treatment Regimens listed below. |</li></ul><a href=#treatment-regimens><h3 id=treatment-regimens><span class=hanchor arialabel=Anchor># </span>Treatment Regimens</h3></a><ul><li>Single drug therapy is usually sufficient; combination therapy used with HIV co-infection.</li></ul><table><thead><tr><th> </th><th>Drug/Dose</th><th>Comments</th></tr></thead><tbody><tr><td>Preferred Regimens</td><td></td><td></td></tr><tr><td><strong>Pegylated-Interferon-alpha 2a</strong> 180 μg sc once weekly  OR</td><td></td><td></td></tr><tr><td><strong>Entecavir</strong> 0.5 mg po once daily OR</td><td></td><td></td></tr><tr><td><strong>Tenofovir alafenamide</strong> (TAF/Vemlidy) 25 mg po once daily</td><td></td><td></td></tr></tbody></table><p>|</p><p>PEG-IFN: Treat for 48 weeks.
Entecavir: Do not use Entecavir if Lamivudine resistance present.
Entecavir/Tenofovir:  Treat for at least 24-48 weeks after seroconversion from HBeAg to anti-HBe. Indefinite chronic therapy for HBeAg negative patients. Renal impairment dose adjustments necessary.</p><p>|
| Alternative Regimens |</p><p><strong>Lamivudine</strong> 100 mg po once daily OR
<strong>Telbivudine</strong> 600 mg po once daily OR
<strong>Emtricitabine</strong> 200 mg po once daily (investigational) OR
<strong>Adefovir</strong> 10 mg po once daily OR
<strong>Tenofovir disproxil</strong> (TDF) 300 mg po once daily</p><p>| These alternative agents are rarely used except in combination. When used, restrict to short term therapy owing to high rates of development of resistance. Not recommended as first-line therapy. Use of Adefovir has mostly been replaced by Tenofovir. |
| Preferred Regimen
for HIV-HBV Co-Infected Patient | <strong>Truvada</strong> (Tenofovir disproxil [TDF] 300 mg + Emtricitabine  200 mg) po once daily + another anti-HIV drug | ALL patients if possible as part of a fully suppressive anti-HIV/anti-HBV regimen.  Continue therapy indefinitely. |</p><a href=#prevention><h3 id=prevention><span class=hanchor arialabel=Anchor># </span>Prevention</h3></a><ul><li>See Hepatitis B, Vaccine for indications, available products, dosing, and vaccine characteristics for pre-exposure prevention.</li></ul><a href=#comments><h3 id=comments><span class=hanchor arialabel=Anchor># </span>Comments</h3></a><ul><li>The goal of therapy for HBeAg+ patients is seroconversion from positive to negative (but this rarely occurs). For HBeAg negative patients, the goal is suppression of HBV DNA to &lt; 50IU/mL.</li><li>Summary of sustained viral reposne after one year of therapy. Note: low frequency of loss of HBeAg loss.</li></ul><table><thead><tr><th> </th><th>PEG-IFN2a</th><th>Lamivudine</th><th>Adefovir</th><th>Entecavir</th><th>Telbivudine</th><th>Tenofovir</th></tr></thead><tbody><tr><td>HBeAg Seroconversion</td><td>27%</td><td>16-21%</td><td>12%</td><td>21%</td><td>22%</td><td>21%</td></tr><tr><td>HBV DNA &lt;50IU/mL</td><td>25-63%</td><td>60-73%</td><td>51-64%</td><td>67-90%</td><td>60-88%</td><td>80-95%</td></tr><tr><td>ALT normalization</td><td>39%</td><td>41-75%</td><td>48-61%</td><td>68%</td><td>60%</td><td>77%</td></tr><tr><td>HBeAg loss</td><td>3%</td><td>&lt;1%</td><td>0</td><td>2%</td><td>&lt;1%</td><td>3%</td></tr><tr><td>Viral Resistance</td><td>0</td><td>15-30%</td><td>Minimal</td><td>0</td><td>6%</td><td>0</td></tr><tr><td>Modified from Hepatology 45:507, 2007.</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table><ul><li><strong>All patients with HBV infection should be vaccinated against Hepatitis A.  Add link to Hepatitis A, Vaccines</strong></li><li><strong>All patients with HBV should be evaluated for presence of Hepatitis D (HDV or Delta) virus infection.</strong></li><li>Interferon best used in HBeAg+ patients; much higher conversion rates from HBeAg+ to HBeAg- and from HBsAg+ to HBsAg- with IFN compared to nucleoside regimens.</li><li><strong>IFN therapy</strong> favored in <strong>Genotype A (and B)</strong> patients; and those who have lower HBV DNA, higher ALT, younger age, and women, all have higher seroconversion response rates.</li><li>For those who seroconvert from HBeAg to anti-HBe, if consolidation therapy for one additional year, 20% will sero-revert back to HBeAg+ status within 1 – 3 years.  Ongoing monitoring is required for all patients.</li><li><strong>NOTE:  Return to active HBV replicative state, including HBsAg sero-reversion, spikes in HBV DNA, and liver inflammation / damage, can occur when HBV infected patients receive chemotherapy or immunomodulating agents!</strong> This is especially a concern when using Rituxin or for those patients receiving Stem Cell Transplantation.  Use of a nucleoside agent recommended prior to the initiation of chemotherapy and /or immunotherapy in HBsAg positive patients and in selected HBsAg-, anti-HBS+, anti-HBc+ patients.</li><li>All patients with cirrhosis, HBeAg+ status, older patients, and those with a positive family history of HCC should have periodic (every 6 months) screening for HCC with an ultrasound, with or without an alpha-fetoprotein assay.</li><li><strong>Resistance</strong>:  Lamivudine, Telbivudine, and Adefovir, when used as monotherapy is associated with high level resistance.  Frequency of emergence of mutations increases with duration of therapy (> 6 months).  Reviewed in Lancet Inf Dis. 12: 341, 2012.</li><li><strong>Combination Therapy:</strong> Under investigation.  Early studies demonstrate higher rates of virologic success (HBV DNA &lt; 50 IU/ml), HBeAg seroconversion, and possibly less emergence of resistance.  Not yet recommended as primary mode of therapy except where resistance already exists, in patients with HIV-HBV co-infection, and for those with advanced disease and decompensated cirrhosis.</li></ul><p><a class="internal-link broken">inbox</a></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li><a href=/Treatment-for-acute-HBV/ data-ctx="HBV Treatment" data-src=/Treatment-for-acute-HBV class=internal-link>Treatment for acute HBV</a></li><li><a href=/recent/ data-ctx="HBV Treatment" data-src=/recent class=internal-link>recent</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>